Tech Company Financing Transactions

Spero Therapeutics Funding Round

On 4/10/2014, Spero Therapeutics raised $3 million in Series A financing from Atlas Venture, Partners Innovation Fund and SR One Capital Management.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

675 Massachusetts Ave. 14th Floor
Cambridge, MA 02139
USA

Phone

857-242-1600

Website

www.sperotherapeutics.com

Email Address

Not Recorded

Overview

Spero Therapeutics' (Nasdaq: SPRO) vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ankit Mahadevia

        

Chief Financial Officer

Joel Sendek

        

Chief Medical Officer

David Melnick

        

Chief Operating Officer

Cristina Larkin

        

Chief Scientific Officer

Thomas Parr

        

VP - Bus. Development

Timothy Keutzer

        

VP - Bus. Development

Scott Peterson

        

VP - Finance

Steve Garbacz

        

VP - R & D

Troy Lister

        

VP - Regulatory Affairs

Carol Waldo

        

Browse more venture capital transactions:

Prev: 4/10/2014: JeNu Biosciences venture capital transaction
Next: 4/10/2014: Muut venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary